

W Nicol Keith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1371100/publications.pdf>

Version: 2024-02-01

118
papers

10,314
citations

46918

47
h-index

33814

99
g-index

119
all docs

119
docs citations

119
times ranked

15907
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Pyrazolopyrimidine Ligand of Human PGK1 and Stress Sensor DJ1 Modulates the Shelterin Complex and Telomere Length Regulation. <i>Neoplasia</i> , 2019, 21, 893-907.	2.3	4
2	Diversity of Institutional Support for Research Impact Implementation. <i>Zeitschrift Für Diversitätsforschung Und -management</i> , 2019, , 200-208.	0.1	0
3	Extensive telomere erosion is consistent with localised clonal expansions in Barrett's metaplasia. <i>PLoS ONE</i> , 2017, 12, e0174833.	1.1	6
4	A "synthetic-sickness" screen for senescence re-engagement targets in mutant cancer backgrounds. <i>PLoS Genetics</i> , 2017, 13, e1006942.	1.5	9
5	Abstract 1356: Cell-based screening to identify repressors of wild type and mutated telomerase reverse transcriptase gene promoter activity. , 2016, , .		0
6	Identification of a Selective G1-Phase Benzimidazolone Inhibitor by a Senescence-Targeted Virtual Screen Using Artificial Neural Networks. <i>Neoplasia</i> , 2015, 17, 704-715.	2.3	18
7	Broad targeting of angiogenesis for cancer prevention and therapy. <i>Seminars in Cancer Biology</i> , 2015, 35, S224-S243.	4.3	375
8	Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. <i>Seminars in Cancer Biology</i> , 2015, 35, S55-S77.	4.3	95
9	Broad targeting of resistance to apoptosis in cancer. <i>Seminars in Cancer Biology</i> , 2015, 35, S78-S103.	4.3	535
10	Cancer prevention and therapy through the modulation of the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2015, 35, S199-S223.	4.3	285
11	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. <i>Seminars in Cancer Biology</i> , 2015, 35, S5-S24.	4.3	231
12	Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. <i>Seminars in Cancer Biology</i> , 2015, 35, S25-S54.	4.3	468
13	Therapeutic targeting of replicative immortality. <i>Seminars in Cancer Biology</i> , 2015, 35, S104-S128.	4.3	49
14	A multi-targeted approach to suppress tumor-promoting inflammation. <i>Seminars in Cancer Biology</i> , 2015, 35, S151-S184.	4.3	95
15	Immune evasion in cancer: Mechanistic basis and therapeutic strategies. <i>Seminars in Cancer Biology</i> , 2015, 35, S185-S198.	4.3	1,122
16	Tissue invasion and metastasis: Molecular, biological and clinical perspectives. <i>Seminars in Cancer Biology</i> , 2015, 35, S244-S275.	4.3	408
17	Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition. <i>Molecular Biology of the Cell</i> , 2015, 26, 2971-2985.	0.9	42
18	Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2015, 35, S276-S304.	4.3	220

#	ARTICLE	IF	CITATIONS
19	Plasma N-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome. <i>Future Oncology</i> , 2015, 11, 193-203.	1.1	2
20	Mathematical Model of a Telomerase Transcriptional Regulatory Network Developed by Cell-Based Screening: Analysis of Inhibitor Effects and Telomerase Expression Mechanisms. <i>PLoS Computational Biology</i> , 2014, 10, e1003448.	1.5	13
21	Immortalization of T-Cells Is Accompanied by Gradual Changes in CpG Methylation Resulting in a Profile Resembling a Subset of T-Cell Leukemias. <i>Neoplasia</i> , 2014, 16, 606-615.	2.3	14
22	Isolation, Culture, and Transfection of Melanocytes. <i>Current Protocols in Cell Biology</i> , 2014, 63, 1.8.1-20.	2.3	30
23	MicroRNA and Senescence: The Senectome, Integration and Distributed Control. <i>Critical Reviews in Oncogenesis</i> , 2013, 18, 373-390.	0.2	27
24	Response to "Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanisms". <i>Oncogene</i> , 2012, 31, 267-268.	2.6	0
25	Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. <i>Neuro-Oncology</i> , 2012, 14, 736-744.	0.6	21
26	A Small Molecule Modulator of Prion Protein Increases Human Mesenchymal Stem Cell Lifespan, Ex Vivo Expansion, and Engraftment to Bone Marrow in NOD/SCID Mice. <i>Stem Cells</i> , 2012, 30, 1134-1143.	1.4	31
27	Progeroid syndromes: models for stem cell aging?. <i>Biogerontology</i> , 2012, 13, 63-75.	2.0	1
28	Cancer cell senescence: a new frontier in drug development. <i>Drug Discovery Today</i> , 2012, 17, 269-276.	3.2	49
29	Mesenchymal Stem Cells as Therapeutic Delivery Vehicles Targeting Tumor Stroma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 767-773.	0.7	35
30	Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 490-503.	1.5	28
31	Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 179-186.	1.6	24
32	Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. <i>BMC Genomics</i> , 2010, 11, 532.	1.2	27
33	Telomerase upregulation is a postcrisis event during senescence bypass and immortalization of two Nijmegen breakage syndrome T cell cultures. <i>Aging Cell</i> , 2010, 9, 220-235.	3.0	19
34	TCEAL7 Inhibition of c-Myc Activity in Alternative Lengthening of Telomeres Regulates hTERT Expression. <i>Neoplasia</i> , 2010, 12, 405-416.	2.3	28
35	Mining Cellular Senescence for Drug Targets. , 2010, , 235-265.		2
36	Modulation of Gene Expression Using Zinc Finger-Based Artificial Transcription Factors. <i>Methods in Molecular Biology</i> , 2010, 649, 117-132.	0.4	7

#	ARTICLE	IF	CITATIONS
37	Abstract 738: Design and synthesis of novel N10-protected pyrrolobenzodiazepine (PBD) prodrugs for use in nitroreductase-mediated GDEPT therapies. , 2010, , .		0
38	Dynamic Telomerase Gene Suppression via Network Effects of GSK3 Inhibition. PLoS ONE, 2009, 4, e6459.	1.1	34
39	A role for NANOG in G1 to S transition in human embryonic stem cells through direct binding of CDK6 and CDC25A. Journal of Cell Biology, 2009, 184, 67-82.	2.3	177
40	The PTEN regulator DJâ€1 is associated with hTERT expression in clear cell renal cell carcinoma. International Journal of Cancer, 2009, 125, 783-790.	2.3	52
41	A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene, 2009, 28, 3765-3774.	2.6	64
42	A systems biology approach to Down syndrome: Identification of Notch/Wnt dysregulation in a model of stem cells aging. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 353-363.	1.8	40
43	Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 341-352.	1.8	105
44	Downregulation of Multiple Stress Defense Mechanisms During Differentiation of Human Embryonic Stem Cells. Stem Cells, 2008, 26, 455-464.	1.4	240
45	Targeting telomerase for cancer therapeutics. British Journal of Cancer, 2008, 98, 677-683.	2.9	149
46	Telomerase redefined: Integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie, 2008, 90, 13-23.	1.3	112
47	High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. British Journal of Cancer, 2008, 98, 1467-1474.	2.9	25
48	Silencing of the expression of pluripotent driven-reporter genes stably transfected into human pluripotent cells. Regenerative Medicine, 2008, 3, 505-522.	0.8	21
49	Targeting Telomerase: Therapeutic Options for Cancer Treatment. , 2008, , 247-283.		4
50	Epigenetic control of cellular senescence in disease: opportunities for therapeutic intervention. Expert Reviews in Molecular Medicine, 2007, 9, 1-26.	1.6	10
51	Modulation of Telomerase Promoter Tumor Selectivity in the Context of Oncolytic Adenoviruses. Cancer Research, 2007, 67, 1299-1307.	0.4	31
52	Stem cell ageing: does it happen and can we intervene?. Expert Reviews in Molecular Medicine, 2007, 9, 1-20.	1.6	1,506
53	Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells. Drug Discovery Today, 2007, 12, 611-621.	3.2	30
54	Ectopically hTERT expressing adult human mesenchymal stem cells are less radiosensitive than their telomerase negative counterpart. Experimental Cell Research, 2007, 313, 1056-1067.	1.2	53

#	ARTICLE	IF	CITATIONS
55	Therapeutic potential of adult stem cells. <i>European Journal of Cancer</i> , 2006, 42, 1243-1246.	1.3	53
56	Cancer stem cells: Opportunities for novel diagnostics and drug discovery. <i>European Journal of Cancer</i> , 2006, 42, 1195-1196.	1.3	5
57	Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. <i>Oncogene</i> , 2006, 25, 61-69.	2.6	89
58	Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell. <i>Regenerative Medicine</i> , 2006, 1, 125-131.	0.8	51
59	Transcriptional Repression of Telomerase RNA Gene Expression by c-Jun-NH2-Kinase and Sp1/Sp3. <i>Cancer Research</i> , 2006, 66, 1363-1370.	0.4	36
60	Lack of Telomerase Gene Expression in Alternative Lengthening of Telomere Cells Is Associated with Chromatin Remodeling of the <i>hTR</i> and <i>hTERT</i> Gene Promoters. <i>Cancer Research</i> , 2005, 65, 7585-7590.	0.4	101
61	Dysregulated expression of the major telomerase components in leukaemic stem cells. <i>Leukemia</i> , 2005, 19, 381-389.	3.3	42
62	Application of Targeted Radiotherapy/Gene Therapy to Bladder Cancer Cell Lines. <i>European Urology</i> , 2005, 47, 250-256.	0.9	13
63	MDM2 negatively regulates the human telomerase RNA gene promoter. <i>BMC Cancer</i> , 2005, 5, 6.	1.1	24
64	Synthetic Anticancer Gene Medicine Exploits Intrinsic Antitumor Activity of Cationic Vector to Cure Established Tumors. <i>Cancer Research</i> , 2005, 65, 8079-8084.	0.4	136
65	Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. <i>Annals of Oncology</i> , 2005, 16, 1646-1653.	0.6	43
66	Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm. <i>Clinical Cancer Research</i> , 2005, 11, 3766-3772.	3.2	296
67	The <i>hTERT</i> and <i>hTERC</i> Telomerase Gene Promoters Are Activated by the Second Exon of the Adenoviral Protein, E1 A, Identifying the Transcriptional Corepressor CtBP as a Potential Repressor of Both Genes. <i>Neoplasia</i> , 2005, 7, 614-622.	2.3	21
68	Properties of a Telomerase-Specific Cre/Lox Switch for Transcriptionally Targeted Cancer Gene Therapy. <i>Neoplasia</i> , 2005, 7, 1020-1029.	2.3	14
69	Detection of Telomerase <i>hTERT</i> Gene Expression and Its Splice Variants by RT-PCR. , 2004, 97, 297-310.		9
70	Detection of Telomerase Enzyme Activity by TRAP Assay. , 2004, 97, 311-322.		3
71	Noninvasive Imaging of the Transcriptional Activities of Human Telomerase Promoter Fragments in Mice. <i>Cancer Research</i> , 2004, 64, 4906-4911.	0.4	71
72	From stem cells to cancer: balancing immortality and neoplasia. <i>Oncogene</i> , 2004, 23, 5092-5094.	2.6	35

#	ARTICLE	IF	CITATIONS
73	Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate. <i>Prostate Cancer and Prostatic Diseases</i> , 2004, 7, 355-363.	2.0	15
74	Gastrokine 1 is abundantly and specifically expressed in superficial gastric epithelium, down-regulated in gastric carcinoma, and shows high evolutionary conservation. <i>Journal of Pathology</i> , 2004, 203, 789-797.	2.1	94
75	A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria. <i>BMC Hematology</i> , 2004, 4, 3.	2.6	28
76	An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. <i>Journal of Gene Medicine</i> , 2004, 6, 937-947.	1.4	57
77	Drug Insight: cancer cell immortality—telomerase as a target for novel cancer gene therapies. <i>Nature Clinical Practice Oncology</i> , 2004, 1, 88-96.	4.3	42
78	Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus. <i>Neoplasia</i> , 2004, 6, 85-92.	2.3	11
79	In Situ Analysis of Telomerase RNA Gene Expression as a Marker for Tumor Progression. , 2003, 75, 163-176.		0
80	Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. <i>Oncogene</i> , 2003, 22, 370-380.	2.6	81
81	Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. <i>Oncogene</i> , 2003, 22, 4287-4300.	2.6	68
82	Involvement of NF-Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene. <i>FEBS Letters</i> , 2003, 536, 111-119.	1.3	33
83	Why a Special Issue on Gene Therapy?. <i>Journal of Biomedicine and Biotechnology</i> , 2003, 2003, 1-2.	3.0	0
84	Telomerase-directed molecular therapeutics. <i>Expert Reviews in Molecular Medicine</i> , 2002, 4, 1-25.	1.6	35
85	Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. <i>Gut</i> , 2002, 50, 373-377.	6.1	134
86	Analysis of Telomerase RNA Gene Expression by In Situ Hybridization. , 2002, 191, 65-82.		6
87	?Senescence-associated? ?-galactosidase activity in the upper gastrointestinal tract. <i>Journal of Pathology</i> , 2002, 196, 394-400.	2.1	56
88	Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. <i>Cancer Research</i> , 2002, 62, 5999-6005.	0.4	58
89	Expression of telomerase RNA in oesophageal and oral cancer. <i>Journal of Oral Pathology and Medicine</i> , 2001, 30, 577-581.	1.4	16
90	Telomerase and cancer: time to move from a promising target to a clinical reality. <i>Journal of Pathology</i> , 2001, 195, 404-414.	2.1	51

#	ARTICLE	IF	CITATIONS
91	Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. <i>Oncogene</i> , 2001, 20, 7797-7803.	2.6	103
92	Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill. <i>Oncogene</i> , 2001, 20, 7804-7808.	2.6	35
93	Senescence-associated beta galactosidase (SABGal) activity in normal, metaplastic and dysplastic mucosae of the upper GI tract. <i>Gastroenterology</i> , 2000, 118, A275.	0.6	0
94	Activation of Telomerase RNA Gene Promoter Activity by NF-Y, Sp1, and the Retinoblastoma Protein and Repression by Sp3. <i>Neoplasia</i> , 2000, 2, 531-539.	2.3	44
95	Mapping of the Gene for the Human Telomerase Reverse Transcriptase, hTERT, to Chromosome 5p15.33 by Fluorescence in Situ Hybridization. <i>Neoplasia</i> , 2000, 2, 197-201.	2.3	81
96	Genetic Analysis of Drug Resistance by Fluorescence In Situ Hybridization. , 1999, 28, 209-224.		0
97	Genetic Analysis of Drug Resistance by Reverse In Situ Hybridization. , 1999, 28, 225-234.		0
98	Is small cell lung cancer the perfect target for anti-telomerase treatment?. <i>Carcinogenesis</i> , 1999, 20, 1649-1652.	1.3	49
99	Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. <i>Oncogene</i> , 1999, 18, 5646-5653.	2.6	213
100	Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage. <i>British Journal of Cancer</i> , 1999, 81, 684-689.	2.9	34
101	Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. , 1999, 24, 306-314.		111
102	Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization. <i>Oncogene</i> , 1998, 16, 979-983.	2.6	74
103	Cloning and characterization of human and mouse telomerase RNA gene promoter sequences. <i>Oncogene</i> , 1998, 16, 1345-1350.	2.6	84
104	Identification of genetic changes associated with drug resistance by reverse in situ hybridization. <i>British Journal of Cancer</i> , 1997, 75, 275-282.	2.9	13
105	Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. <i>Oncogene</i> , 1997, 14, 1013-1021.	2.6	180
106	Chromosomal and genetic alterations of 7,12- Dimethylbenz[a]anthracene-induced melanoma from TP-ras transgenic mice. , 1997, 20, 78-87.		25
107	Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. <i>British Journal of Cancer</i> , 1996, 74, 508-512.	2.9	64
108	Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. <i>British Journal of Cancer</i> , 1996, 74, 502-507.	2.9	66

#	ARTICLE	IF	CITATIONS
109	Differential expression of DNA topoisomerase II α and β in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. British Journal of Cancer, 1996, 74, 1869-1876.	2.9	47
110	Somatic cell hybrids. Trends in Biochemical Sciences, 1995, 20, 331.	3.7	0
111	Interphase cytogenetic analysis of erbB2 and topoisomerase II co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. International Journal of Cancer, 1995, 64, 18-26.	2.3	56
112	Molecular analysis of the topoisomerase II α gene and its expression in human ovarian cancer. Annals of Oncology, 1994, 5, 75-81.	0.6	20
113	Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. International Journal of Cancer, 1994, 59, 607-611.	2.3	71
114	Expression of topoisomerase II α and β in an adenocarcinoma cell line carrying amplified topoisomerase II α and retinoic acid receptor α genes. British Journal of Cancer, 1993, 68, 793-800.	2.9	21
115	Amplification of the topoisomerase II α gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II α and β loci in normal tissue. Genes Chromosomes and Cancer, 1992, 4, 169-175.	1.5	21
116	Retrovirus mediated transfer and expression of GM-CSF in haematopoietic cells. British Journal of Cancer, 1990, 62, 388-394.	2.9	11
117	Expression of mdr1 and gst- π in human breast tumours: comparison to in vitro chemosensitivity. British Journal of Cancer, 1990, 61, 712-716.	2.9	89
118	Expression in U87 glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131 I]MIBG and clonogenic cell kill. , 0, .		1